The Company is a Verified Federal
Government Vendor (CAGE CODE # 8QXV4)
NEW YORK, NY -- April 1, 2021 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of CBD & CBG
infused Supplement chewing gums (Flavors: Pomegranate, Blood
Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional
product offerings, as well as an ongoing Pharmaceutical Development
initiative, today announced that it has successfully registered on
BidNet Direct (“BidNet”) and is actively bidding on U.S. Government
contract(s). On October 6, 2020, the Company announced that it had
been officially approved to operate as a U.S. Government Vendor.
Since then, the Company has strategically broadened and diversified
its product offerings and is excited about this potential revenue
stream.
BidNet is the most trusted name in government bidding, providing
vendors with government opportunities specifically targeted by
industry and geographic area. BidNet is now working directly
with over 1,100 local government agencies as a bid and vendor
management solution. BidNet Direct is comprised of multiple
purchasing groups throughout the country. Through these purchasing
groups, government agencies utilize the network to publish,
distribute and award contracts. Vendors receive exclusive bid
opportunities, directly from the buying agency.
The Following Credentials were Issued to Tauriga Sciences, Inc.
by the United States Government:
Commercial & Government Entity (“CAGE”) Code#: 8QXV4
Purpose of Registration: ALL AWARDS
Expiration Date: 10/01/2021
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating,
diversified life sciences company, engaged in several major
business activities and initiatives. The company
manufactures and distributes several proprietary retail products
and product lines, mainly focused on the Cannabidiol (“CBD”) and
Cannabigerol (“CBG”) Edibles market segment. The main
product line, branded as Tauri-Gum™, consists of a proprietary
supplement chewing gum that is Kosher certified, Halal certified,
and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood
Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon,
Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear
Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey),
& (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden
Raspberry). The Company’s commercialization strategy consists
of a broad array of retail customers, distributors, and a
fast-growing E-Commerce business segment (E-Commerce
website: www.taurigum.com). Please visit our
corporate website, for additional information, as well as
inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing
Pharmaceutical Development initiative. This relates to the
development of a proposed Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed for the
following indication: Patients Subjected to Ongoing Chemotherapy
Treatment). On March 22, 2021, the Company announced that it had
Converted its U.S. Provisional Patent Application (filed on March
17, 2020) into a U.S. Non-Provisional Patent Application. The
Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD
COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF
TREATMENT”. On December 18, 2020 the Company disclosed that
it had entered into a Master Services Agreement with CSTI to lead
the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New
York. In addition, the Company operates two full time
E-Commerce fulfillment centers: one located in Montgomery, Texas
and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward-looking statements due to known and
unknown risks and uncertainties, such as are not guarantees of
general economic and business conditions, the ability to
successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other periodic filings made from time to time with the
Securities and Exchange Commission. Such forward-looking statements
are made only as of the date of this release, and Tauriga assumes
no obligation to update forward-looking statements to reflect
subsequent events or circumstances. You should not place undue
reliance on these forward-looking statements.
There can be no guarantee that the Company will generate any
future revenue, from bidding on U.S. Government contract(s).
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
Cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024